[vc_row][vc_column][vc_column_text]A new study, published in JAMA, has found that glucagon-like peptide-1 receptor agonists (GLP-1RA) – such as Ozempic, Wegovy and Mounjaro – do not increase the risk of pancreatic cancer. This finding is significant as it addresses concerns raised by earlier studies that suggested a possible association between GLP-1 receptor agonists and pancreatic cancer. Popularity […]

Ozempic, Wegovy, do not increase risk of pancreatic cancer: new study